ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

LY4405094

A development code.

Its studies are mostly in Alzheimer Disease, led by Eli Lilly.

Furthest: phase 1, since Aug 24, 20262 company-led studies, 2 open or runningNext primary completion: Jan 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly22 open or runningphase 1since Aug 24, 2026Aug 24, 2026Jan 2028phase 1 · NCT07787182

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 24, 2026First studies: 2 phase 1 studies in Alzheimer DiseaseFirst studyNCT07787182, NCT07787169

Ahead

  1. Jan 2028Primary completion: phase 1 study in Alzheimer DiseaseNCT07787182
  2. Jul 2028Primary completion: phase 1 study in Alzheimer DiseaseNCT07787169

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07787182Alzheimer Disease · United States, China, Japan1RecruitingJan 202868
NCT07787169Alzheimer Disease · United States, China, Japan1RecruitingJul 2028179

How it is read

Names in the registry

  • “LY4405094”, 4 entries

Codes read as this program: LY4405094.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.